Literature DB >> 7093981

Pharmacokinetic behavior of S-carboxymethylcysteine-Lys in patients with chronic bronchitis.

P C Braga, M Borsa, L De Angelis, R Bossi, L Allegra, F Scaglione, G Scarpazza.   

Abstract

A mass fragmentographic technique was used to study the pharmacokinetic behavior of SCMC-Lys in patients with acute exacerbations of chronic bronchitis and with dense expectoration. Serum and urine levels, as well as bronchial mucus levels and their correlations, were determined. The data suggest that SCMC-Lys diffuses well into bronchial mucus, a useful feature for a mucolytic drug.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7093981

Source DB:  PubMed          Journal:  Clin Ther        ISSN： 0149-2918            Impact factor:   3.393


  5 in total

Review 1.  Environmental toxicity, redox signaling and lung inflammation: the role of glutathione.

Authors:  Saibal K Biswas; Irfan Rahman
Journal:  Mol Aspects Med       Date:  2008-08-08

Review 2.  Antioxidant therapeutic advances in COPD.

Authors:  Irfan Rahman
Journal:  Ther Adv Respir Dis       Date:  2008-12       Impact factor: 4.031

Review 3.  Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis.

Authors:  Zheng Zeng; Dan Yang; Xiaoling Huang; Zhenliang Xiao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-02

Review 4.  Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.

Authors:  Elisabetta Pace; Isa Cerveri; Donato Lacedonia; Gregorino Paone; Alessandro Sanduzzi Zamparelli; Rossella Sorbo; Marcello Allegretti; Luigi Lanata; Francesco Scaglione
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

Review 5.  The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.

Authors:  C Hooper; J Calvert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.